WCM/EADO 2021 | Triplet therapies for advanced metastatic melanoma
Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, outlines the use of triplet therapies for the treatment of metastatic melanoma, highlighting data from the KEYNOTE-022 trial (NCT02130466), the IMspire150 trial (NCT02908672) and the COMBI-i trial (NCT02967692) all of which have reported contrasting results. The KEYNOTE-022 trial is exploring pembrolizumab in combination with trametinib and dabrafenib in advanced melanoma. The IMspire150 trial (NCT02908672) is studying atezolizumab plus cobimetinib and vemurafenib for BRAF-mutated melanoma. The COMBI-i trial is investigating the anti-PD-1 antibody PDR001 in combination with dabrafenib and trametinib for advanced melanoma. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Paolo Ascierto, MD, has participated in a consultancy or advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore and Seagen; has received research funding from Bristol Myers Squibb, Roche-Genentech, Array and Sanofi; and has received travel support from MSD.
